Idecabtagene vicleucel is an autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. Multiple myeloma is a cancer where plasma cells rapidly divide out of control.
- Mechanism
- Curator reviewed · 9 references
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.
The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain. The single chain variable fragment (scFv) allows for B-cell maturation antigen specificity of the CAR. The CD23ζ cytoplasmic domain mediates T-cell activation by CD2, a T-cell surface adhesion molecule. 4-1BB enhances cytotoxic T-cell activity as well as the production of interferon-γ.
Idecabtagene vicleucel binds to B-cell maturation antigen expressing cells. Binding to the target leads to proliferation of idecabtagene vicleucel, secretion of cytokines, and lysis of the targeted cells.
- Primary indication
- Idecabtagene vicleucel is indicated to treat adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an antiCD38 monoclonal antibody.Curator reviewed · 5 structured indications
- First approval
- Canada, 2021 · United States, 2021 · European Union, 2021
- Also known as
- Anti-BCMA CAR T cell · IDE-CEL
- Code names
- BB-2121 · BMS-986395
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Idecabtagene vicleucel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account